This phenomenon extends to in vivo testing in SCLC xenograft models where combination treatment with ABT-199 and the BCL-XL-specific mimetic resulted in better survival than treatment with ABT-263 alone [46]. The gene discussed is BCL2L1; the disease is small cell lung carcinoma.